Venus Consent Decree Shows Cost Of Flouting GMP Warning
This article was originally published in The Tan Sheet
Executive Summary
Venus Pharmaceuticals International agrees to stop production and distribution of supplements in the U.S. and internationally, and to recall and destroy affected product made prior to January 2012 due to repeated violations of GMP regulations that brought the firm a warning letter from FDA in May.
You may also be interested in...
Tracking Federal Agencies’ Enforcement In Supplement Space
““The Tan Sheet” provides links to previous articles on many of the enforcements DoJ announced from its year-long sweep.
Tracking Federal Agencies’ Enforcement In Supplement Space
““The Tan Sheet” provides links to previous articles on many of the enforcements DoJ announced from its year-long sweep.
Basic GMP Failures Will Prompt Heightened FDA Scrutiny
FDA supplement programs director Dan Fabricant and food and drug law attorney Marc Ullman reflect on the ongoing struggles of many supplement firms to meet good manufacturing practice standards. “‘I don’t have the resources to comply’ is not an excuse. Then get out of the business,” Ullman says.